VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZNTL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZNTLZentalis Pharmaceuticals, Inc.
$1.49$106M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksZNTLCash Flow

Zentalis Pharmaceuticals, Inc. (ZNTL) Cash Flow Statement

8Y historyFree accessUpdated daily

Operating cash flow of -$70.2M in 2026Q2 and zero dividends or buybacks indicate persistent cash burn with no internal funding source, suggesting the company may depend on external capital to sustain operations.

Income StatementBalance SheetCash FlowRatios

ZNTL Cash Flow Statement

Annual statement

ZNTL Cash Flow Statement

Zentalis Pharmaceuticals, Inc. (ZNTL) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-166.79M-125.25M-170.86M-207.82M-163.75M-154.09M-86.83M-39.14M-24.25M
Operating CF Margin %---253.41%------173221.43%
Operating CF Growth %-102.45%26.7%17.79%-26.91%-6.27%-77.48%-121.81%-61.41%-
Net Income-141.67M-137.06M-165.87M-292.19M-237.11M-166.09M-118.55M-46.38M-23.43M
Depreciation & Amortization613K739K1.29M1.39M1.43M544K160K111K51K
Stock-Based Compensation12.75M20.72M67.27M54.82M46.84M35.74M23.15M617K308K
Deferred Taxes000-853K-769K-2.51M17K02.37M
Other Non-Cash Items5.08M-526K-57.01M23.15M12.61M-38.38M556K0-2.37M
Working Capital Changes-8.21M-9.12M-16.54M5.86M13.25M16.61M7.84M6.51M-1.18M
Change in Receivables05M-5M00413K-277K777K-254K
Change in Inventory000000-5.52M0-1.86M
Change in Payables-7.58M-17.32M-18.02M10.92M15.53M13.96M14.31M7.12M977K
Cash from Investing67.19M131.62M176.56M-44.46M-114.18M-18.11M-284.83M-352K-227K
Capital Expenditures-68K0-221K-583K-2.55M-6.11M-758K-352K-227K
CapEx % of Revenue--0.33%-----1621.43%
Acquisitions569K065K0111.63K-14.32M18.42M00
Investments---------
Other Investing-440K698K00-111.63K0-18.42M00
Cash from Financing80.49M-4.28M108K237.3M261.04M178.52M360.44M81.83M9.47M
Debt Issued (Net)000000000
Equity Issued (Net)83.4M-4.28M349K237.3M261.04M179.67M342.01M81.88M9.47M
Dividends Paid000000000
Share Repurchases000000000
Other Financing-2.91M0-241K00-1.15M18.42M-46K0
Net Change in Cash-19.11M2.09M5.81M-14.98M-16.89M6.31M-11.22M42.34M-15.01M
Free Cash Flow-166.86M-125.25M-171.08M-208.41M-166.3M-160.2M-87.58M-39.49M-24.48M
FCF Margin %---253.74%------174842.86%
FCF Growth %-24.52%26.79%17.91%-25.32%-3.81%-82.91%-121.76%-61.35%-
FCF per Share-1.97-1.74-2.41-3.19-3.15-3.75-2.13-1.10-1.36
FCF Conversion (FCF/Net Income)1.18x0.91x1.03x0.71x0.69x0.97x0.74x0.86x1.15x
Interest Paid000000000
Taxes Paid00359K140K12K20K18K15K4K

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Persistent operating cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Losses Mirror Operating Cash Burn

Based on reported quarterly figures, ZNTL's operating cash flow has tracked net losses closely, with OCF/NI ratios mostly between 0.68 and 1.29 across recent quarters, indicating losses are largely cash-based rather than accrual-driven.

The ratio of operating cash flow to net income sits near 0.9 in the latest quarters, which suggests reported losses are predominantly real cash outflows rather than non-cash charges. The 2024Q1 positive net income of $10.1M alongside a -$52.0M operating cash outflow, however, illustrates how earnings can diverge sharply from cash in individual periods. Investors should monitor whether this near-parity persists, as it leaves little accounting cushion against the ongoing burn.

Free Cash Flow Deeply Negative Throughout

As reported in the quarterly data, ZNTL's free cash flow ranged from -$70.2M in 2026Q2 to -$27.0M in 2025Q3, with no period showing positive FCF across the ten quarters provided.

Free cash flow has remained negative in every reported quarter, and the most recent figure of -$70.2M represents the sharpest outflow in the series, roughly double the prior quarter. Because no revenue is reported in recent periods, FCF margin cannot be meaningfully computed, so the trajectory must be judged on absolute burn. This pattern suggests the company's funding requirement is continuous and may warrant further investigation into the runway implied by current cash reserves.

Negligible Capital Intensity Profile

Based on reported figures, ZNTL's capital expenditures were minimal, at or near zero in most quarters and never exceeding $181K, indicating a capital-light operating model.

Capex has been virtually absent, with the only nonzero entries being small outflows in 2024Q1 and 2024Q2 and a $34K charge in the two most recent quarters. Depreciation and amortization of roughly $150K to $330K per quarter aligns with this light asset base. The low capital intensity suggests the cash burn is driven by operating expenses, primarily research and development, rather than by investment in physical infrastructure.

No Shareholder Returns Amid Burn

According to the reported cash flow statements, ZNTL paid no dividends and executed no share repurchases across all ten quarters, with acquisition outflows appearing only sporadically and in small amounts.

The absence of dividends and buybacks is consistent with a company consuming cash to fund development rather than returning it. Acquisition activity appears limited to small figures such as $569K and $564K, which do not materially affect the overall deployment picture. Capital allocation therefore reflects a single priority, sustaining operations, and any future capital raise would likely be directed toward that same use.

Stock Compensation Masks True Cost

Based on reported figures, stock-based compensation reached $31.4M in 2024Q4 and $6.4M in 2026Q2, meaning a portion of the operating cost base is non-cash and may understate economic dilution.

Adding back stock-based compensation to operating cash flow would still leave the company deeply cash-negative, so the core burn conclusion holds regardless. However, the non-cash equity cost represents real dilution borne by existing shareholders that does not appear in free cash flow. Analysts should weigh per-share economics rather than cash burn alone when assessing the true cost of the current operating structure.

ZNTL — Frequently Asked Questions

Quick answers to the most common questions about buying ZNTL stock.

How much cash does Zentalis Pharmaceuticals, Inc. (ZNTL) generate from operations?

Zentalis Pharmaceuticals, Inc. (ZNTL) generated $-125.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Zentalis Pharmaceuticals, Inc.'s free cash flow?

Zentalis Pharmaceuticals, Inc. (ZNTL) reported negative free cash flow of $125.2M in 2025, indicating capital requirements exceeded cash from operations.

What is Zentalis Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Zentalis Pharmaceuticals, Inc. (ZNTL) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.